Iron replacement therapy in cancer-related anemia (Q37872140)

24 August 2017

1 reference

title

Iron replacement therapy in cancer-related anemia (English)

1 reference

24 August 2017

David Baribeault

1

1 reference

24 August 2017

Michael Auerbach

series ordinal

2

1 reference

24 August 2017

publication date

1 May 2011

1 reference

American Journal of Health-System Pharmacy

24 August 2017

published in

1 reference

24 August 2017

volume

68

1 reference

24 August 2017

issue

10 Suppl 1

1 reference

24 August 2017

page(s)

S4-14; quiz S15-6

1 reference

Prevalence and outcomes of anemia in cancer: a systematic review of the literature

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Chemotherapy-induced anemia in adults: incidence and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Anaemia of cancer: an overview of mechanisms involved in its pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Anaemia of cancer: impact on patient fatigue and long-term outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Anemia of chronic disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Clinical update: intravenous iron for anaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Hepcidin and its role in regulating systemic iron metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Intravenous iron: from anathema to standard of care

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Intravenous iron in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

A randomized controlled study of iron supplementation in patients treated with erythropoietin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Can intravenous iron therapy meet the unmet needs created by the new restrictions on erythropoietic stimulating agents?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Update on adverse drug events associated with parenteral iron

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

On the relative safety of parenteral iron formulations

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Use of parenteral iron products and serious anaphylactic-type reactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Intravenous iron as standard of care in oncology: opportunity lost.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

The development of erythropoietic agents in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

Ferumoxytol for treating iron deficiency anemia in CKD

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110039

31 March 2020

Identifiers

DOI

10.2146/AJHP110039

1 reference

24 August 2017

1 reference